Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07224035 · ClinicalTrials.gov registry record · Phase 4
Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community- AIM 1
A Phase 4 study of Gastric Cancer and H. Pylori Infection, sponsored by University of Miami.
- Active
- Registry status
- Phase 4
- Development phase
- 500
- Enrollment target
- 1
- Study location
NCT07224035: Active Phase 4 study of Gastric Cancer and H. Pylori Infection, sponsored by University of Miami.
NCT07224035 is a Phase 4 study of Gastric Cancer and H. Pylori Infection that is active but no longer recruiting, run by University of Miami. The registered enrollment target is 500 participants, above the 316-participant average among 153 other Gastric Cancer trials with a reported enrollment target (58% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07224035, a Phase 4 study of Gastric Cancer and H. Pylori Infection, is active but no longer recruiting, sponsored by University of Miami.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
H. pylori is an infection of the stomach that can cause chronic gastritis, gastric cancer and peptic ulcer disease. The goal of this study is to screen people for this infection and offer treatment for those who test positive for the infection. By treating those who are positive for H. pylori, there is an opportunity to prevent gastritis, peptic ulcer disease, and even gastric cancer.
Primary Outcome
This measure determines the percent of participants who test positive for Helicobacter pylori at baseline. This is done using the PYTEST® 14C-Urea Breath Test. Participants will receive a diagnosis on-site, approximately 30 minutes after administration of urea capsule. This will allow immediate treatment free of charge (VOQUEZNA® Triple Pak®) initiation for positive eligible participants.
Conditions Studied
Interventions
- DRUG PYTEST® 14C-Urea Breath Test
- DRUG VOQUEZNA® Triple Pak®
Study Locations (1)
Florida
- University of Miami - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2022-10-15 |
| Est. Completion | 2027-11-06 |
| Phase | Phase 4 |
What the registry record for NCT07224035 still lists
NCT07224035 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, above the 316-participant average among 153 other Gastric Cancer trials with a reported enrollment target (58% higher).
The record links to 3 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 2 interventions - of which PYTEST® 14C-Urea Breath Test is the first listed.
NCT07224035 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT07224035 about?
NCT07224035 is a clinical study titled "Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community- AIM 1". H. pylori is an infection of the stomach that can cause chronic gastritis, gastric cancer and peptic ulcer disease. The goal of this study is to screen people for this infection and offer treatment for those who test positive for the infection. By treating those who are positive for H. pylori, there...
What is the current status of trial NCT07224035?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 500 participants. The study started on 2022-10-15. Estimated completion is 2027-11-06.
What conditions does trial NCT07224035 study?
This clinical trial studies the following conditions: Gastric Cancer, H. Pylori Infection, H Pylori Gastritis.
What interventions are being tested in trial NCT07224035?
The interventions under investigation include: PYTEST® 14C-Urea Breath Test (DRUG), VOQUEZNA® Triple Pak® (DRUG).
Who is sponsoring clinical trial NCT07224035?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07224035 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastric Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07224035's enrollment target sits among peer trials
500 24th of 153 higher than 128 of 153 other Gastric Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gastric Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Intraoperative Imaging of Gastrointestinal Malignancies Using Pafolacianine (CYTALUX™)
RECRUITING · Phase 4
-
Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community-AIM 2
ACTIVE NOT RECRUITING · Phase 4
-
Improving Complete Endoscopic Mucosal Resection (EMR) of Colorectal Neoplasia
COMPLETED · Phase 4
-
CONFIRM: Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI